A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia

Inclusion Criteria: * Signed Written Informed Consent * Subjects with chronic phase chronic myeloid leukemia (CML) * Subjects resistant/intolerant to imatinib * Subjects presenting: 1. ECOG performance status (PS) score 0-2 2. Adequate hepatic function 3. Adequate renal function 4. Adequate lung function Exclusion Criteria: * Concurrent malignancy other than CML * Women who are pregnant or breastfeeding * Concurrent pleural effusion * Uncontrolled or significant cardiovascular disease * A serious uncontrolled medical disorder that would impair the ability of the subjects to receive protocol therapy. * Prior therapy with dasatinib * Subjects with T315I and/or F317L BCR-ABL point mutations